MedTrace Logo

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

NCT05945927 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 178

Last updated 2025-10-10

No results posted yet for this study

Summary

This study is a post-marketing, observational, multicenter, prospective study. It will investigate the the safety and effectiveness of T-DM1 in the Chinese population in real-world clinical practice.

Conditions

Interventions

DRUG

Trastuzumab emtansine

Trastuzumab emtansine will be administered as per local clinical practice and local labeling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-13
Primary Completion
2025-08-30
Completion
2025-08-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05945927 on ClinicalTrials.gov